glp 1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders glp 1 parkinson's disease and

PLIVA also began testing the drug in humans

Adjusting doses without professional supervision can increase risks, including poor blood sugar control

The first application of an IC vaccine was in the prevention of infectious bursa disease (IBD) in poultry

confirmed that alcohol intake upregulates miR-155 to reduce the protein expression of Lysosomal-associated membrane protein 1 and 2 (LAMP1 and LAMP2) in the liver, leading to impaired autophagy function of lysosomes and reduced autophagy flux (Lu et al., 2023a)

Compounded preparations in multi-dose vials face greater contamination risk with each needle puncture, which is why the post-opening window is shorter